Endothelin-1 inhibitors in chronic pancreatitis

September 17, 2009,

Fibrosis is a key feature of chronic pancreatitis and pancreatic cancer. The extensive deposition of extracellular matrix proteins fosters the development of an exocrine and endocrine organ insufficiency, and accelerates progression of the tumour. Pancreatic stellate cells (PSC) are the principal effector cells in pancreatic fibrosis. They are activated by profibrogenic mediators, which include, for example, cytokines and ethanol metabolites. So far, there are no therapies available to interfere with fibrogenesis in the diseased organ.

A better understanding of the cellular and molecular mechanisms of PSC activation represents an important prerequisite for the development of novel therapeutic approaches aimed at the treatment of pancreatic fibrosis in the context of inflammation and cancer.

A research article to be published on September 7, 2009 in the World Journal of Gastroenterology addresses this question. The results of the study by Jonitz et al. provide insights into the effects of the extracellular mediator endothelin-1 (ET-1) in PSC. They indicate that ET-1 stimulates activation of the cells, thereby promoting fibrosis. At the molecular level, the authors have identified molecules (ERK1/2, p38 and AP-1) that mediate the ET-1 signal, and linked them to the process of stellate cell activation. Furthermore, the two proinflammatory cytokines β and interleukin-6 were found to be expressed in ET-1-treated PSC, suggesting, for the first time, a direct link between inflammation and fibrosis at the level of ET-1 action.

In addition, studies on the regulation of ET-1 synthesis revealed that transforming growth factor-β1 and tumour necrosis factor-α strongly stimulate ET-1 secretion by PSC. Together, the results of the study by Jonitz et al. suggest that ET-1 is part of a network of proinflammatory and profibrogenic mediators that fosters interactions between inflammatory cells and PSC, ultimately enhancing inflammation and fibrosis. The authors suggest further experimental studies to elucidate the efficiency of endothelin receptor antagonists in pancreatic fibrosis.

The prognosis of pancreatic cancer is the worst of any common human tumour. is a disease with limited therapeutic options in a significant proportion of patients, and also represents a risk factor of . Inhibition of accompanying fibrosis might become a novel adjuvant approach to treat both diseases in the future, once specific antifibrotic agents become available.

More information: Jonitz A, Fitzner B, Jaster R. Molecular determinants of the profibrogenic effects of endothelin-1 in pancreatic stellate cells. World J Gastroenterol 2009; 15(33): 4143-4149 www.wjgnet.com/1007-9327/15/4143.asp

Source: World Journal of Gastroenterology (news : web)

Related Stories

Recommended for you

Researchers discover novel mechanism linking changes in mitochondria to cancer cell death

February 20, 2018
To stop the spread of cancer, cancer cells must die. Unfortunately, many types of cancer cells seem to use innate mechanisms that block cancer cell death, therefore allowing the cancer to metastasize. While seeking to further ...

Stem cell vaccine immunizes lab mice against multiple cancers

February 15, 2018
Stanford University researchers report that injecting mice with inactivated induced pluripotent stem cells (iPSCs) launched a strong immune response against breast, lung, and skin cancers. The vaccine also prevented relapses ...

Induced pluripotent stem cells could serve as cancer vaccine, researchers say

February 15, 2018
Induced pluripotent stem cells, or iPS cells, are a keystone of regenerative medicine. Outside the body, they can be coaxed to become many different types of cells and tissues that can help repair damage due to trauma or ...

Team paves the way to the use of immunotherapy to treat aggressive colon tumors

February 15, 2018
In a short space of time, immunotherapy against cancer cells has become a powerful approach to treat cancers such as melanoma and lung cancer. However, to date, most colon tumours appeared to be unresponsive to this kind ...

Can our genes help predict how women respond to ovarian cancer treatment?

February 15, 2018
Research has identified gene variants that play a significant role in how women with ovarian cancer process chemotherapy.

First comparison of common breast cancer tests finds varied accuracy of predictions

February 15, 2018
Commercially-available prognostic breast cancer tests show significant variation in their abilities to predict disease recurrence, according to a study led by Queen Mary University of London of nearly 800 postmenopausal women.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.